European Approval and Legal VictoryThe positive developments extended beyond U.S. borders as the European Commission granted market authorization for Eli Lilly's Alzheimer's treatment. A federal judge ruled that the regulatory agency acted unlawfully by refusing to classify Eli Lilly's obesity and diabetes treatment Retatrutide as a biological product. Eli Lilly confirmed it is "actively engaged in discussions with the government to further enhance patient access." Quarterly Results Loom as Critical TestThe current optimism faces its next critical examination when Eli Lilly discloses third-quarter results in late October. AdFresh Eli Lilly information released.